Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

216.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,329
Open 216.00
Bid (Size) 218.00 (200)
Ask (Size) 220.00 (100)
Prev. Close 216.00
Today's Range 216.00 - 216.00
52wk Range 35.42 - 216.72
Shares Outstanding 106,313,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗
Small-cap stocks are finally recovering after years of underperforming the major indexes. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗
Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+173.3%
+173.3%
1 Month
+19.7%
+19.7%
3 Month
+46.6%
+46.6%
6 Month
+114.7%
+114.7%
1 Year
+492.6%
+492.6%

More News

Read More
Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗
Via Chartmill
Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗
Via Benzinga
News headline image
Revolution Medicines Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗
Via The Motley Fool
News headline image
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗
Via The Motley Fool
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
Via The Motley Fool
News headline image
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
From Revolution Medicines, Inc.
Via GlobeNewswire
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗
Via The Motley Fool
News headline image
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗
Via The Motley Fool
News headline image
Can Revolution Medicines Be a Game-Changer Stock? ↗
Via The Motley Fool
News headline image
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗
Via The Motley Fool
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Via The Motley Fool
News headline image
This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake ↗
Via The Motley Fool
Topics Energy Regulatory Compliance

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?
Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.
What exchange does Revolution Medicines, Inc. - Common Stock trade on?
Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?
The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market
What is the current price of Revolution Medicines, Inc. - Common Stock?
The current price of Revolution Medicines, Inc. - Common Stock is 216.00
When was Revolution Medicines, Inc. - Common Stock last traded?
The last trade of Revolution Medicines, Inc. - Common Stock was at 08/18/26 04:00 PM ET
What is the market capitalization of Revolution Medicines, Inc. - Common Stock?
The market capitalization of Revolution Medicines, Inc. - Common Stock is 22.96B
How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?
Revolution Medicines, Inc. - Common Stock has 23B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.